Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

How to show more historical data? Use the zoom-out option. You can add up to 100 technical indicators to your graph, such as Linear Regression, CCI, ADX, and many more. In our commitment to ...

Tirzepatide trailed only behind CagriSema, a combination of semaglutide and cagrilintide yet to be released. While more research is necessary, Duah said that Zepbound (tirzepatide) may be more ...

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical ...

hDepartment of Medicine, VA Eastern Colorado Health Care System and University of Colorado School of Medicine, Aurora, CO, USA iSchool of Medicine, University of New Mexico Health Sciences Center, ...

A 2024 Lancet Series on antimicrobial resistance used findings from some of these studies and others to summarise the current state of antibiotic resistance and recommended several global targets to ...